Adaptive clinical trial designs in oncology

Yong Zang, J. Jack Lee

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.

Original languageEnglish (US)
Article number49
JournalChinese Clinical Oncology
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Clinical Trials
Random Allocation
Biomarkers
Pharmaceutical Preparations
Sample Size
Costs and Cost Analysis
Therapeutics

Keywords

  • Adaptive design
  • Adaptive randomization
  • Biomarker-guided design
  • Interim analysis
  • Seamless design

ASJC Scopus subject areas

  • Oncology

Cite this

Adaptive clinical trial designs in oncology. / Zang, Yong; Lee, J. Jack.

In: Chinese Clinical Oncology, Vol. 3, No. 4, 49, 01.01.2014.

Research output: Contribution to journalReview article

@article{aef76b6512ab468eb1932223993c2227,
title = "Adaptive clinical trial designs in oncology",
abstract = "Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.",
keywords = "Adaptive design, Adaptive randomization, Biomarker-guided design, Interim analysis, Seamless design",
author = "Yong Zang and Lee, {J. Jack}",
year = "2014",
month = "1",
day = "1",
doi = "10.3978/j.issn.2304-3865.2014.06.04",
language = "English (US)",
volume = "3",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "4",

}

TY - JOUR

T1 - Adaptive clinical trial designs in oncology

AU - Zang, Yong

AU - Lee, J. Jack

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.

AB - Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.

KW - Adaptive design

KW - Adaptive randomization

KW - Biomarker-guided design

KW - Interim analysis

KW - Seamless design

UR - http://www.scopus.com/inward/record.url?scp=84941349403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941349403&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2304-3865.2014.06.04

DO - 10.3978/j.issn.2304-3865.2014.06.04

M3 - Review article

AN - SCOPUS:84941349403

VL - 3

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 4

M1 - 49

ER -